Literature DB >> 17109631

High-potentiality preliminary selection criteria and transformation time-dependent factors analysis for establishing Epstein-Barr virus transformed human lymphoblastoid cell lines.

I-C Chang1, J-Y Wu, H-I Lu, H-W Ko, J-L Kuo, C-Y Wang, P-S Shen, S-M Hwang.   

Abstract

Infection of freshly isolated and cryopreserved lymphocytes with Epstein-Barr virus (EBV) leads to the establishment of human B lymphoblastoid cell lines (LCLs). Techniques for optimal infection of the lymphocytes are vital for the establishment of a human biobank. The present study found that more than half (58-86%) of such established LCLs had transport times of less than 48 h, cell densities exceeding 10(6) cells/ml and cell viabilities greater than 90%. After EBV infection, 3306 freshly isolated lymphocytes required 30.0 +/- 0.1 days to become LCLs. Conversely, 1210 cryopreserved lymphocytes required 36.2 +/- 0.4 days. Cell density and viability of the culture affected transformation time in freshly isolated lymphocytes. On the other hand, blood transport time, cryopreservation time and initial cell viability were major factors in cryopreserved specimens. These results contribute to general information concerning the establishment of a human biobank for EBV infected cells.

Entities:  

Mesh:

Year:  2006        PMID: 17109631      PMCID: PMC6496667          DOI: 10.1111/j.1365-2184.2006.00404.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  17 in total

1.  Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.

Authors:  M R Sarrias; S Franchini; G Canziani; E Argyropoulos; W T Moore; A Sahu; J D Lambris
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

2.  Successful transformation of cryopreserved lymphocytes: a resource for epidemiological studies.

Authors:  J C Beck; C M Beiswanger; E M John; E Satariano; D West
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-05       Impact factor: 4.254

3.  Whole blood cryopreservation in epidemiological studies.

Authors:  Richard B Hayes; Craig O Smith; Wen-Yi Huang; Yvonne Read; William C Kopp
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-11       Impact factor: 4.254

4.  Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus.

Authors:  A J Sinclair; P J Farrell
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

5.  Successful use of long-term frozen lymphocytes for the establishment of lymphoblastoid cell lines.

Authors:  S Tremblay; E W Khandjian
Journal:  Clin Biochem       Date:  1998-10       Impact factor: 3.281

6.  CD21-mediated entry and stable infection by Epstein-Barr virus in canine and rat cells.

Authors:  L Yang; S Maruo; K Takada
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  CD19 signalling improves the Epstein-Barr virus-induced immortalization of human B cell.

Authors:  D Y Hur; M H Lee; J W Kim; J-H Kim; Y K Shin; J K Rho; K B Kwack; W J Lee; B G Han
Journal:  Cell Prolif       Date:  2005-02       Impact factor: 6.831

8.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells.

Authors:  D R Martin; R L Marlowe; J M Ahearn
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  An efficient method for the rapid establishment of Epstein-Barr virus immortalization of human B lymphocytes.

Authors:  H-M Oh; J-M Oh; S-C Choi; S-W Kim; W-C Han; T-H Kim; D-S Park; C-D Jun
Journal:  Cell Prolif       Date:  2003-08       Impact factor: 6.831

View more
  5 in total

1.  Viable mononuclear cell stability study for implementation in a proficiency testing program: impact of shipment conditions.

Authors:  Olga A Kofanova; Kristine Davis; Barbara Glazer; Yvonne De Souza; Joseph Kessler; Fotini Betsou
Journal:  Biopreserv Biobank       Date:  2014-06       Impact factor: 2.300

2.  Capacity of robot handling for Epstein-Barr virus transformation.

Authors:  I-C Chang; H-W Ko; S-M Hwang
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

3.  Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.

Authors:  Vahid Younesi; Forough Golsaz Shirazi; Ali Memarian; Amir Amanzadeh; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Cytotechnology       Date:  2013-02-13       Impact factor: 2.058

4.  CYP17A1 intron mutation causing cryptic splicing in 17α-hydroxylase deficiency.

Authors:  Daw-Yang Hwang; Chi-Chih Hung; Felix G Riepe; Richard J Auchus; Alexandra E Kulle; Paul-Martin Holterhus; Mei-Chyn Chao; Mei-Chuan Kuo; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

5.  Efficient and reliable establishment of lymphoblastoid cell lines by Epstein-Barr virus transformation from a limited amount of peripheral blood.

Authors:  Natsue Omi; Yuichi Tokuda; Yoko Ikeda; Morio Ueno; Kazuhiko Mori; Chie Sotozono; Shigeru Kinoshita; Masakazu Nakano; Kei Tashiro
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.